updated analysis of phase iii trial of idelalisib combined with bendamustine and rituximab in cll
Published 7 years ago • 200 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
3:35
trial of ibrutinib with bendamustine and rituximab in cll: results and study design
-
2:25
update from murano trial: venetoclax-rituximab leads to slower clonal growth rate in cll
-
1:18
updates from current cll clinical trials
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
4:03
a review of current and future directions of clinical trials for cll
-
13:41
progress report ii - andrea lancz
-
3:13
cll versus other leukemia types
-
1:01:22
chronic lymphocytic leukemia at ash21: what's new?
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
2:59
clinical trial updates and time-limited therapy in cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:56
the future of fixed-duration therapy in cll
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:28
the future of cll treatment
-
2:41
cell avidity as a predictor of t-cell efficacy